-
Pliant Therapeutics NASDAQ:PLRX Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Location: 260 Littlefield Avenue, Suite 150, California, 94080, US | Website: pliantrx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
329.3M
Cash
404.5M
Avg Qtr Burn
-33.24M
Short % of Float
15.29%
Insider Ownership
2.91%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bexotegrast (PLN-74809) Details Idiopathic pulmonary fibrosis | Phase 2b Data readout | |
Bexotegrast (PLN-74809) Details Primary sclerosing cholangitis | Phase 2a Update | |
PLN-101325 Details Duchenne muscular dystrophy | Phase 1 Initiation | |
PLN-101095 Details Solid tumor/s, Cancer | Phase 1a Data readout | |
Failed Discontinued |